Gen 9 Revenue, Growth & Competitor Profile

Company Profile & Annual Report for Gen 9

Access the complete profile.

Gen 9 Fast Facts

Revenue	N/A    See Exact Annual Revenue
Employees	N/AExact Company Size
Primary Industry	5417 Scientific Research & Development Services
Additional NAICS Codes	541711 Research & Development in Biotechnology
Address	840 Memorial Drive Cambridge, MA 02139

Note: Revenues for privately held companies are statistical evaluations.


Gen 9's Annual Report & Profile shows critical firmographic facts:

• What is the company's size? (Annual sales and employees)
  • Gen 9's annual revenues are N/A (see exact revenue data)
• What industry is the company in?
  • Gen 9 is classified as operating in the Scientific Research & Development Services industry, NAICS Code 5417.

Investor Activity

Gen 9 has actively raised capital from investors. These investors may include private investors, venture capital firms, or other investment vehicles.

Date	Investors	Percent Raised	Target Size
July 30, 2014	4	100%	$25 MM
Complete list of funding rounds and total amounts in the Company Report

Trademark Applications

Trademark applications show the products and services that Gen 9 is developing and marketing. Gen 9 doesn't have any recent trademark applications, indicating Gen 9 is focusing on its existing business rather than expanding into new products and markets. Trademarks may include brand names, product names, logos and slogans.

Trademark	Date
GENEPRINTER Device for synthesis of DNA and DNA products, namely, nucleic acids, peptides, proteins, cells, reagents, organic molecules, nucleic acid analogs, peptide analogs, protein analogs, nucleic acid arrays, peptide arrays, and protein arrays for laboratory purposes and scientific research purposes	05/24/2016
GEN9 Custom manufacturing in the nature of synthesis and assembly of nucleic acids, proteins and cells	05/15/2014
GENEBYTE PLUS Custom manufacturing services in connection with the synthesis and assembly of nucleic acids, peptides, proteins, cells, nucleic acid arrays, peptide arrays, and protein arrays	04/22/2014

See all trademarks and details in the Full Report.

Market Share of Gen 9's Largest Competitors

A competitive analysis shows these companies are in the same general field as Gen 9, even though they may not compete head-to-head. These are the largest companies by revenue. However, they may not have the largest market share in this industry if they have diversified into other business lines. The "Competition" section of a business plan or investment memorandum would start by analyzing the information about these companies. Competitive advantage comes from offering better pricing or superior products/service.

Company	Headquarters	Revenue ($ MM)
LEIDOS	Denver, CO	100
NATIONAL TECHNOLOGY & ENGINEERING SOLUTIONS OF SANDIA	Albuquerque, NM	30
INC RESEARCH	Raleigh, NC	27
RESEARCH FOUNDATION FOR STATE UNIVERSITY OF NEW YORK	Albany, NY	17
FLUOR MARINE PROPULSION	West Mifflin, PA	15
SYNEOS HEALTH	Raleigh, NC	13
ILLUMINA	San Diego, CA	12
UT-BATTELLE	Oak Ridge, TN	11
PRA HOLDINGS	Raleigh, NC	11

Nearby Competitors

These companies are similar in business line and location to Gen 9. While some companies compete with neighboring businesses for customers, other companies may compete to attract skilled employees.

Company	Headquarters	Revenue ($ MM)
BROAD INSTITUTE	Cambridge, MA	100
BEIGENE USA	Cambridge, MA	69
ALNYLAM PHARMACEUTICALS	Cambridge, MA	52
SAGE THERAPEUTICS	Cambridge, MA	47
INTELLIA THERAPEUTICS	Cambridge, MA	35
IPSEN BIOPHARMACEUTICALS	Cambridge, MA	34

Other Companies at 840 Memorial Drive, Cambridge MA

Company	Headquarters	Revenue ($ MM)
MERSANA THERAPEUTICS	Cambridge, MA	100
BLUEBIRD BIO	Cambridge, MA	38
MARENGO THERAPEUTICS	Cambridge, MA	30
DIMENSIONS THERAPUTICS	Cambridge, MA	21
CORVIUM	Cambridge, MA	18

Future Competition: Gen 9's Fastest Growing Competitors

These companies are in the same general field as Gen 9 and are rapidly expanding. Companies may grow organically or through acquisition. In some cases apparently high growth rates may be caused by data that weren't available in previous years.

Company	Revenue ($ MM)